Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VIVESTO ADR OASMY

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics,... see more

Recent & Breaking News (GREY:OASMY)

Oasmia Pharmaceutical AB Appoints Fredrik Gynnerstedt as Chief Financial Officer

GlobeNewswire August 31, 2016

Exclusive: Oasmia Chairman Talks About How They're Changing Cancer Drug Delivery Treatment

Benzinga.com  August 26, 2016

Oasmia successfully completes a private placement of new convertible instruments in a total amount of SEK 42,000,000

GlobeNewswire June 10, 2016

Year-end report for the fiscal year May 1, 2015 - April 30, 2016

GlobeNewswire June 3, 2016